Axogen to buy BioCircuit for $200 million cash and sells $208.7 million in new stock
Axogen agreed on September 9, 2026 to acquire BioCircuit Technologies for a base price of $200.0 million in cash, subject to customary adjustments, with closing expected in the fourth quarter of 2026. On September 10 it priced an offering of 4,910,000 common shares at $42.50 each, with gross proceeds of about $208.7 million before underwriting discounts and expenses, which it plans to use mainly to fund the purchase. Shareholders face new share issuance and the risk that the deal does not close on the expected timeline.
Key points
- Merger: $200.0 million base cash price; $1.0 million withheld at closing for post-closing adjustments; either party may terminate if not completed by December 31, 2026; no termination fee.
- Offering: 4,910,000 shares at $42.50 per share; underwriters pay $39.95 per share; a 30-day option covers up to 736,500 more shares; closing expected September 11, 2026.
- Gross proceeds of about $208.7 million (before discounts and expenses, excluding the option); the offering is not conditioned on the merger closing.
- BioCircuit's investor presentation cites about $24 million run-rate revenue (Q2 2026 annualized) and $11 million of 2025 revenue.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.